Inactive Instrument

Analyst Reco. Celldex Therapeutics, Inc. Nasdaq

Equities

US15117B1035

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

TD Cowen Initiates Celldex Therapeutics at Outperform Rating	Dec. 20	MT
Wells Fargo Upgrades Celldex Therapeutics to Equalweight From Underweight With $27 Price Target	Nov. 10	MT
HC Wainwright Adjusts Price Target on Celldex Therapeutics to $80 From $73, Maintains Buy Rating	Nov. 06	MT
Rate Cut Hopes Push Exchange-Traded Funds, Equity Futures Higher Pre-Bell Monday	Nov. 06	MT
Wells Fargo Starts Celldex Therapeutics With Underweight Rating, $21 Price Target	23-08-22	MT
ANALYST RECOMMENDATIONS : Applovin, BAE Systems, Evercore, Jefferies, Target...	23-08-22
Guggenheim Adjusts Price Target on Celldex Therapeutics to $63 From $68, Maintains Buy Rating	22-11-11	MT
SVB Securities Adjusts Celldex Therapeutics' Price Target to $64 From $68, Keeps Outperform Rating	22-08-09	MT
HC Wainwright Adjusts Celldex Therapeutics' Price Target to $73 from $60, Keeps Buy Rating	22-07-01	MT
CELLDEX THERAPEUTICS : Jefferies & Co Reinstates Coverage on Celldex Therapeutics With Buy Rating, $66 Price Target	21-09-17	MT
ANALYST RECOMMENDATIONS : Autoliv, Fortinet, Tesla, Virgin Galactic, WP Carey...	21-09-17
CELLDEX THERAPEUTICS : HC Wainwright Adjusts Celldex Therapeutics PT to $60 From $54, Maintains Buy Rating	21-09-13	MT
CELLDEX THERAPEUTICS : SVB Leerink Starts Celldex Therapeutics at Outperform with $68 Price Target	21-09-10	MT
CELLDEX THERAPEUTICS : HC Wainwright Adjusts Celldex Therapeutics' Price Target to $54 From $50, Reiterates Buy Rating	21-08-06	MT
CELLDEX THERAPEUTICS : Guggenheim Starts Celldex Therapeutics at Buy With $66 Price Target	21-07-22	MT
CELLDEX THERAPEUTICS : HC Wainwright Adjusts Price Target on Celldex Therapeutics to $50 From $36, Reiterates Buy Rating	21-07-12	MT
Celldex Therapeutics : Reports 80% Complete Response Rate in CDX-0159 Study	21-03-29	MT
Celldex Reports 80% Complete Response Rate in Interim Data Update from Phase 1b study of CDX-0159 in Chronic Inducible Urticaria	21-03-29	CI
CELLDEX THERAPEUTICS : HC Wainwright & Co. Adjusts Price Target on Celldex Therapeutics to $36 From $25, Maintains Buy Rating	21-02-23	MT
CELLDEX THERAPEUTICS : Cantor Fitzgerald Adjusts Celldex Therapeutics PT to $35 From $22, Maintains Overweight Rating	21-02-23	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Celldex Therapeutics, Inc. Nasdaq

Equities

US15117B1035

Analyst Reco.

Filters